.Attributes Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- drug conjugate (ADC) tisotumab vedotin resulted in improved progression-free and general survival, leading to FDA approval as well as a brand new treatment choice for individuals.